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ncreasingly, patients with systemic 
lupus erythematosus (SLE) are 
recognized to have central nervous 
system (CNS) manifestations. Overt 
inﬂ  ammation in the CNS is rare, but 
impairment of cognition or mood 
disturbance is common. Treatment 
of inﬂ  ammation is directed at the 
underlying autoimmune disorder; 
treatment of other manifestations, 
including mood disorder, often focuses 
on symptom alleviation. Cognitive 
impairment in particular appears 
to be progressive and unrelated to 
disease activity, and, at the present 
time, untreatable. One interesting 
aspect of neuropsychiatric lupus is that 
symptoms may remit as well as progress. 
With no known pathophysiology 
for the cognitive impairment or mood 
disturbance seen in SLE, and no ability 
to track the dynamic state of either 
of these symptom complexes, it has 
been difﬁ  cult to develop a meaningful 
classiﬁ  cation of neuropsychiatric SLE 
or a mechanistic understanding of 
these aspects of the disease process. 
There is possible mechanistic 
precedent for neuropsychiatric lupus 
in a number of disease syndromes in 
which anti-neuronal antibodies cause 
damage in the CNS. Often these 
antibodies arise as a consequence of 
microbial infection and cross-react 
with microbial antigens, as in post-
streptococcal movement disorders [1], 
post-infectious polyradiculopathies [2], 
and tropical spastic paraparesis [3]. 
Anti-Neuronal Antibodies in SLE
Recently, a novel pathophysiology for 
cognitive decline and mood disorder in 
SLE has been proposed: cross-reacting 
anti-DNA, anti-N-methyl-D-aspartate 
receptor (NMDAR; see Glossary) 
antibodies mediating neuronal damage 
or death. These antibodies bind a 
5–amino acid epitope D/E W D/E Y 
S/G in the extracellular domains of 
the NR2A and NR2B subunits of the 
NMDAR [4–9]. 
Emerging clinical information about 
the frequency of these anti-DNA, anti-
NMDAR antibodies in patients with 
SLE suggests that 30%–50% of patients 
have these antibodies [10–14]. In one 
longitudinal study, brain dysfunction 
correlated with the presence of 
antibody to DWEYS peptide in the 
cerebrospinal ﬂ  uid, and symptom 
severity correlated with antibody titer 
[10]. But cross-sectional analyses of 
neuropsychological function and 
serum anti-NMDAR antibody levels 
have yielded conﬂ  icting data [11–13]. 
Two studies found a signiﬁ  cant 
correlation between anti-NMDAR 
antibodies and depression [12,13] and 
one study found a correlation with 
neuropsychiatric disease manifestations 
[10]. Another study failed to show 
a correlation between anti-NMDAR 
antibodies and disease manifestations 
[11]; however, these investigators 
required more extensive cognitive 
impairment for diagnosis. 
A New Technique to Study 
Neuronal Damage
In a new study in PLoS Medicine, 
Emmer and colleagues attempted to 
test whether the presence of the anti-
NMDAR antibody correlates with brain 
abnormality [15]. The abnormality was 
assessed by an emerging quantitative 
magnetic resonance imaging 
technique—diffusion weighted images 
(DWIs) and the use of the apparent 
diffusion coefﬁ  cient (ADC). DWIs 
and the ADC offer the promise of a 
quantitative physiological measure 
of cellular integrity from magnetic 
resonance images. ADCs measure 
the movement of water molecules 
that are systematically altered in 
circumstances of subacute, acute, 
and chronic tissue inﬂ  ammation, 
injury, and destruction. Using various 
magnetic resonance stimulation data 
acquisition and processing schemes, an 
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Glossary
D/E W D/E Y S/G: A 5–amino acid 
consensus sequence recognized by lupus 
antibodies and present in the NR2A and 
NR2B subunits of the NMDA receptor.
DWEYS peptide: The antigen used in 
enzyme-linked immunosorbent assays to 
look for anti-NMDA receptor antibodies.
Epitope: An antigenic determinant 
recognized by an antibody molecule.
N-methyl-D-aspartate receptor: 
A receptor for a neurotransmitter 
critically involved in learning and 
memory, and present in high density 
in the hippocampus and amygdala.PLoS Medicine  |  www.plosmedicine.org 2187
ADC is generated—“apparent” because 
diffusion in vivo is inhibited by cellular 
structures, membranes, and other 
molecules. 
Pioneering studies of patients with 
multiple sclerosis (MS) and stroke, 
for example, have recently shown 
quantitative structure–function 
relationships between the ADC and 
cognitive impairment in MS [16], and 
the ADC and various states of stressed 
ischemic brain tissue in stroke [17]. 
Based on information gathered from 
studies of stroke, it would appear that 
the regional vascular compromise of 
stroke produces a breakdown in energy 
generation, an increase in intracellular 
(cytotoxic) edema, and a shrinkage of 
the extracellular compartment, leading 
to decreased ADC and hyperintense 
DWIs. This abnormal physiology may 
resolve coincident with the return 
over days of ADC values to normal. 
In chronic MS, there is a loss of tissue 
integrity with increased vasogenic 
edema and high ADC. In contrast, an 
acute intense inﬂ  ammatory reaction 
with increased microglia simultaneously 
stressing and destroying neurons causes 
a fall in diffusion and the ADC. 
Using the ADC to Study 
Neuropsychiatric Lupus
Currently, there are two published 
studies that used the ADC to study 
patients with SLE. One is by some of 
the authors of the new study in PLoS 
Medicine. Their results showed that 
compared to controls, all 11 patients 
with SLE and CNS involvement had 
higher mean ADC values, suggesting 
loss of tissue integrity, perhaps caused 
by the chronic degenerative effects of 
stroke (n = 4) or seizures (n = 3) and 
atrophy [18]. Four of 20 patients in the 
other study had decreased ADC that 
correlated with focal ischemic regions; 
four had increased ADC and chronic 
small strokes from severe hypertension 
[19]. 
In contrast, Emmer at al. now show 
that compared to 12 healthy control 
patients and 21 patients with SLE and 
no symptoms referable to the CNS, 37 
patients with neuropsychiatric lupus 
had decreased mean ADC in the 
hippocampus and amygdala [15]. Of 
the 37 patients with neuropsychiatric 
lupus, 11 had strokes, nine had 
cognitive dysfunction, two had acute 
confusional states, six had mood or 
anxiety disorders, one had psychosis, 
and the others had neuropathy, 
myelopathy, or headache syndromes. 
Additionally, the authors show that 
ADC measured across all forebrain 
grey and white matter is comparable 
in patients with or without disease, 
yet there was regional depression of 
the ADC in the hippocampus and 
amygdala. In a small subgroup of 
patients with anti-NMDAR antibodies 
(n = 4), the ADC was further depressed 
in the amygdala compared to patients 
without anti-NMDAR antibodies. It 
remains to be determined whether 
decreased ADC in the context of 
magnetic resonance structural images 
that show a normal hippocampus 
and amygdala represents a marker 
of neuron stress, as in ischemia, or 
acute inﬂ  ammation as in MS, or both. 
Nevertheless, the application of these 
advanced imaging techniques to 
speciﬁ  c brain regions is remarkable 
in comparison to these authors’ 
earlier ﬁ  ndings [18]. The regionally 
speciﬁ  c depressed ADC conﬁ  ned to 
the hippocampus and amygdala is 
obviously interesting in view of the 
high concentration of NMDAR in these 
regions, and the preliminary studies 
that show a correlation of depression 
and cognitive impairment with anti-
NMDAR antibodies.
Conclusion
At this point the data are tantalizing 
but scant. They do not permit strong 
prediction about the verity of the 
murine model, which depends not only 
on the neurotoxicity of cross-reacting 
anti-DNA, anti-NMDAR antibodies, but 
also on the ability of the anti-NMDAR 
antibodies to gain access to brain 
tissue. Because the magnetic resonance 
techniques used in this study are low 
risk and have the capacity to capture 
phases of a dynamic physiological 
process, the techniques promise to 
assist substantially in deciphering the 
pathogenicity of neuropsychiatric 
lupus.  
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